Technical Data
A4445-10
Aven, CT (Apoptosis Caspase Activation Inhibitor, Cell Death Regulator Aven, PDCD12)
Description:
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a vari ety of diseases such as cancer (reviewed in 1). Aven is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9 (2). It is thought that Aven functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that Aven impedes Apaf-1-mediated caspase activation. Higher levels of Aven mRNA are seen in patients with acute leukemia than in control patients, suggesting that Aven may be useful as a prognostic indicator in leukemia patients (3). Despite its predicted molecular weight, Aven often migrates at 55kD in SDS-PAGE.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-1ug/ml. See A4445-10A for control peptide.
Optimal dilutions to be determined by the researcher.

Positive Control:
Raji cell lysate

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
14 amino acid peptide from near the carboxy terminus of human Aven (GenBank accession no. NP_065104)
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Specificity:
Recognizes human Aven.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lockshin RA, Osborne B, and Zakeri Z. Cell death in the third millennium. Cell Death Differ. 2000; 7:2-7. 2. Chau BN, Cheng EH-Y, Kerr DA, et al. Aven, a novel inhibitor of caspase activation. Binds Bcl-xL and Apaf-1. Mol. Cell 2000; 6:31-40. 3. Paydas S, Tanriverdi K, Yavuz S, et al. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann. Oncology 2003; 14:1045-50.